Compare Fubotv Inc (FUBO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Tango Therapeutics Inc. — how do they compare? Fubotv Inc trades at $8.22 (market cap $901.97M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 4.1× Fubotv Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Tango Therapeutics Inc. for 0 Days on average.
| FUBO | TNGX | |
|---|---|---|
Market Cap | $901.97M | $3.74B |
Volume | 1,439,905 | 3,438,781 |
Sector | Media | Health |
52-Week High | $48.96 | $32.90 |
52-Week Low | $8.09 | $7.50 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.07B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO stock trades at $8.19, down 6.29% today, reflecting a bearish technical signal. Revenue grew to $1.62 billion in 2024, with net losses narrowing to -$172.25 million, indicating improving profitability trends. The company recently expanded sports streaming partnerships, including a multi-year NHL deal announced September 28, 2026, to enhance content offerings.
The outlook is mixed; deep undervaluation metrics like P/S of 0.16 and analyst consensus price target of $63.38 suggest significant upside, but persistent cash burn and competitive pressures in streaming pose risks. Investor sentiment hinges on execution of Disney-backed turnaround plans targeting $300 million EBITDA by FY28.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
